- Home
- Equipment
- usa new york
- cancer patient
Refine by
Cancer Patient Equipment Supplied In New York
5 equipment items found
by:Delcath Systems, Inc. based inNew York, NEW YORK (USA)
Delcath has developed a percutaneous targeted, whole-organ treatment that delivers a select high-dose chemotherapy agent directly to the liver, while controlling systemic side effects, by filtering the chemotherapeutic agent from the blood before returning it to the patient. In the US, our drug/device investigational product is HEPZATO™ KIT (melphalan hydrochloride for ...
by:Acuamark Diagnostics based inNew York, NEW YORK (USA)
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per year (worldwide). Annually, the worldwide economic impact of cancer is estimated by the WHO at $1.2 trillion. ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive (UGN-301) immune responses, both of which are important for fully harnessing the power of the immune system to fight ...
Manufactured by:miR Scientific, LLC based inNew York, NEW YORK (USA)
miR Scientific is a precision healthcare company committed to improving public health by transforming cancer management globally. The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers. The initial test delivered by the miR Disease Management Platform® is the ...
Manufactured by:Protara Therapeutics, Inc. based inNew York, NEW YORK (USA)
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan by Chugai Pharmaceutical Co., ...